Anavex Life Sciences Corp (AVXL)

[Jonjones325]

In all these years, after seeing all of this OLE data in multiple trials with hundreds of patients, Missling has never changed or wavered in emphasizing several phrases including: less dementia, ability to halt and reverse, homeostasis, etc.

You would think these phrases would change if that’s not what he’s seeing. Even in the last PR about CTAD, he left those phrases in there. Boiler plate? Maybe, but I think he’s more particular than that. Even leaving in the economic burden piece to that short PR is purposeful.

I’m feeling a PR this week. A week before that EU conference and a month before CTAD. Would he go to this conference as the “expert” in these types of biomarker driven trials knowing he has failed. Someone posted the topic prior. Probably not.

Would he release TLR after presenting at this trial? That would be messed.

Getting exciting here!